Table S2.
Baseline characteristics of included studies on diabetic macular edema
| Author | Year | Treatment | Age (years) | VA (ETDRS letters) | CMT (μm) | Duration of DM (years) | % PDR | Follow-up (weeks) |
|---|---|---|---|---|---|---|---|---|
| Scott et al28 | 2007 | IVB 1.25 mg vs photocoagulation | 65 | 65 | 411 | NA | NA | 12 |
| Faghihi et al30 | 2008 | IVB 1.25 mg vs photocoagulation | 57 | 63 | 359.6 | NA | NA | 16 |
| Soheilian et al29 | 2009 | IVB 1.25 mg vs photocoagulation | 61.2 | 67 | 333.33 | 10.5 | 6 | 24 |
| Michaelides et al27 | 2010 | IVB 1.25 mg vs photocoagulation | 64.2 | 55 | 494.65 | 14 | NA | 52 |
| Solaiman et al31 | 2010 | IVB 1.25 mg vs photocoagulation | 57 | 58 | 455.88 | 18 | 34 | 24 |
| Nguyen et al45 | 2010 | IVR 0.5 mg vs photocoagulation | 62 | NA | 441.65 | NA | NA | 24 |
| Mitchell et al46 | 2011 | IVR 0.5 mg vs photocoagulation | 63.5 | 63 | 405 | NA | NA | 52 |
Abbreviations: VA, visual acuity; CMT, central macular thickness; ETDRS, early treatment diabetic retinopathy study; DM, diabetes mellitus; IVB, intravitreal bevacizumab; IVR, intravitreal ranibizumab; NA, not applicable; PDR, proliferative diabetic retinopathy; VA, visual acuity.